How do biosimilars sustain value, affordability, and access to oncology care?

Click to increase image sizeClick to decrease image size

Declaration of interest

SS is one of the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL). SS was involved in a stakeholder roundtable on biologics and biosimilars sponsored by Amgen, Pfizer, and MSD; he has participated in advisory board meetings for Pfizer and Amgen; he has contributed to studies on biologics and biosimilars for Hospira, Celltrion, Mundipharma, and Pfizer; and he had speaking engagements for Amgen, Celltrion, and Sandoz. SS is a member of the leadership team of the ISPOR Special Interest Group on Biosimilars.

Reviewers disclosure

A reviewer on this manuscript has disclosed receiving research funding from the following biosimilar manufacturers: Sandoz/Novartis, Hospira/Pfizer, Teva Therapeutic Proteins International (now Adello), Coherus and Mylan; and that they are Deputy Editor in Chief, Journal of Medical Economics and Quantitative Methods Editor, JAMA. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.